Investor Presentaiton

Investor Presentation First six months of 2018 Slide 67 OZEMPIC approved in the USA and in the EU Profile OzempicⓇ label in the USA • Adjunct to diet and exercise to improve glycaemic control Two therapeutic dosages, 0.5 mg and 1 mg • Reduction in HbA1c vs comparators¹ Efficacy Conve- nience Safety Reduction in body weight vs comparators¹ Administered once-weekly To be launched in the OzempicⓇ pen Retinopathy wording similar to insulin labels Cardiovascular safety with number of MACE events in clinical section² 1 Statistically significant reduction compared to comparators: placebo, sitagliptin, exenatide extended- release and insulin glargine U100 (phase 3a SUSTAIN trial programme) 2In SUSTAIN 6, there were 108 MACE events with OzempicⓇ compared to 146 events with placebo, equivalent to an event rate of 6.6% with OzempicⓇ and 8.9% with placebo Trial Patients CV data from SUSTAIN 6 trial in OzempicⓇ EU label Reference to CV results in indication MACE Kaplan-Meier OzempicⓇ label VictozaⓇ label SUSTAIN 6 LEADER 9,340 3,297 Included Included HR: 0.741 HR: 0.872 Included Included 195% confidence interval [0.58;0.95]. 295% confidence interval [0.78;0.97] CV: Cardiovascular; MACE: Major adverse cardiovascular events; HR: Hazard ratio changing diabetes® novo nordisk

View entire presentation